OXFORD BIODYNAMICS PLC
PDMR DEALING/GRANT OF SHARE OPTIONS
London, 19 March 2018: Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, announces that it has today granted 160,000 options over its ordinary shares of 1 pence each to certain employees, including 120,000 options to Paul Stockdale, Chief Financial Officer and a Director of the Company. The options were granted under the Company's 2016 Employee Option Plan, with an exercise price of 170 pence per share.
One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.
Following this grant, Paul Stockdale holds 120,000 options and the notification below, which is made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further details, contact:
|
|
Oxford BioDynamics Plc |
+44 (0)1865 518910 |
Christian Hoyer Millar, CEO |
|
Paul Stockdale, CFO |
|
|
|
Shore Capital |
+44 (0)20 7408 4090 |
Broker and Nominated Adviser |
|
Stephane Auton Edward Mansfield |
|
|
|
FTI Consulting |
+44 (0)20 3727 1000 |
Financial Public Relations Adviser |
|
Brett Pollard |
|
Natalie Garland-Collins |
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
1 |
Details of the person discharging managerial responsibilities/person closely associated |
a) |
Name |
Paul Stockdale |
2 |
Reason for the notification |
a) |
Position/status |
Chief Financial Officer/Director/PDMR |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Oxford BioDynamics Plc |
b) |
LEI |
2138005Y1TK258O5U928 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
b) |
Nature of the transaction |
Grant of share options |
c) |
Price(s) and volume(s) |
120,000 ordinary shares at an exercise price of 170 pence per share |
d) |
Aggregated information - Aggregated volume - Price |
N/A |
e) |
Date of the transaction |
19 March 2018 |
f) |
Place of the transaction |
Outside a trading venue |
